Avedro Inc (NASDAQ:AVDR) shares reached a new 52-week high on Monday . The stock traded as high as $14.20 and last traded at $14.00, with a volume of 8283 shares. The stock had previously closed at $13.36.

Several research analysts have weighed in on the company. Leerink Swann began coverage on Avedro in a report on Monday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Guggenheim began coverage on Avedro in a research note on Monday, March 11th. They issued a “buy” rating and a $21.00 price target on the stock. Svb Leerink began coverage on Avedro in a research note on Monday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. JPMorgan Chase & Co. began coverage on Avedro in a research note on Monday, March 11th. They issued an “overweight” rating and a $16.00 price target on the stock. Finally, Cowen began coverage on Avedro in a research note on Monday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $19.40.

In other news, Director Gilbert H. Kliman purchased 25,000 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were purchased at an average price of $14.00 per share, with a total value of $350,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

ILLEGAL ACTIVITY NOTICE: “Avedro (AVDR) Hits New 1-Year High at $14.20” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/avedro-avdr-hits-new-1-year-high-at-14-20/2900331.html.

About Avedro (NASDAQ:AVDR)

Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.

Recommended Story: What is dollar cost averaging (DCA)?

Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.